2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2109

Hyperferritinemic Syndrome in a General Hospital

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2334

Hypermethylation of NLRP3 Promoter Region Could be Responsible for Decreased Gene Expression, Inflammasome Malfunction and Gut Dysbiosis in Juvenile Spondyloarthritis Patients

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2078

Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2602

Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2125

Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2134

Identification of Multiple Cancer Associated Myositis Specific Antibodies in Idiopathic Inflammatory Myopathies: A Large Longitudinal Cohort Study

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2270

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2057

Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2698

IL-21-mTOR Axis Blocks the Differentiation and Function of SLE Tregs Via Suppression of Autophagy

T Cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 2571

IL23 Deficiency Alters Thymic Selection in Lupus Prone Mice

Systemic Lupus Erythematosus – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2641

Immune Complex-Driven Neutrophil Activation in Systemic Lupus Erythematosus – Novel Biomarkers of Disease Activity and Severity

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2106

Immune-Related Adverse Events in Cancer Patients Treated with Immune Check Point Inhibitors: A Single Center Experience

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2415

Immunogenicity and Persistence of a Prime-Boost Re-Vaccination Strategy for Pneumococcal Vaccines (13-Valent Pneumococcal Conjugate Vaccine + 23-Valent Pneumococcal Polysaccharide Vaccine) in Patients with Rheumatoid Arthritis: A Pilot Study

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2748

Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 1940

Immunologic Synovitis Score: A New Score for Synovial Membrane Characterization in Inflammatory and Non-Inflammatory Arthritis

Biology and Pathology of Bone and Joint Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].